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Background: The randomised phase III TURANDOT trial compared first-line bevacizumab–paclitaxel (BEV–PAC) vs bevacizumab–capecitabine
(BEV–CAP) in HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). The interim analysis revealed no difference in overall survival (OS;
primary end point) between treatment arms; however, progression-free survival (PFS) and objective response rate were significantly superior with
BEV–PAC. We sought to identify patient populations that may be most appropriately treated with one or other regimen.
Methods: Patients with HER2-negative LR/mBC who had received no prior chemotherapy for advanced disease were randomised to either
BEV–PAC (bevacizumab 10mgkg 1 days 1 and 15 plus paclitaxel 90mgm 2 days 1, 8 and 15 q4w) or BEV–CAP (bevacizumab 15mgkg 1 day 1
plus capecitabine 1000mgm 2 bid days 1–14 q3w). The study population was categorised into three cohorts: triple-negative breast cancer
(TNBC), high-risk hormone receptor-positive (HRþ ) and low-risk HRþ . High- and low-risk HRþ were defined, respectively, as havingX2 vsp1 of
the following four risk factors: disease-free interval p24 months; visceral metastases; prior (neo)adjuvant anthracycline and/or taxane; and
metastases in X3 organs.
Results: The treatment effect on OS differed between cohorts. Non-significant OS trends favoured BEV–PAC in the TNBC cohort and BEV–CAP
in the low-risk HRþ cohort. In all three cohorts, there was a non-significant PFS trend favouring BEV–PAC. Grade X3 adverse events were
consistently less common with BEV–CAP.
Conclusions: A simple risk factor index may help in selecting bevacizumab-containing regimens, balancing outcome, safety profile and patient
preference. Final OS results are expected in 2015 (ClinicalTrials.gov NCT00600340).
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Three randomised phase III trials (E2100 (Miller et al, 2007)
AVADO (Miles et al, 2010) and RIBBON-1 (Robert et al, 2011))
demonstrated that adding bevacizumab to first-line chemotherapy
for locally recurrent or metastatic breast cancer (LR/mBC)
significantly improves progression-free survival (PFS; primary
end point) and objective response rate (ORR), but not overall
survival (OS). Two of the regimens evaluated in these trials
(bevacizumab plus weekly paclitaxel (BEV–PAC) in E2100 (Miller
et al, 2007) and bevacizumab plus capecitabine (BEV–CAP) in
RIBBON-1 (Robert et al, 2011)) are approved by health authorities
in many countries worldwide but not in the USA. Two subsequent
trials in the first-line setting, CALGB 40502 (Rugo et al, 2012) and
TURANDOT (Lang et al, 2013), compared different bevacizumab-
containing regimens. CALGB 40502 compared BEV–PAC vs
bevacizumab combined with either nanoparticle albumin-bound
(nab)-paclitaxel or ixabepilone. TURANDOT compared the two
approved bevacizumab-containing regimens, that is, BEV–PAC vs
BEV–CAP. Importantly, despite the inherent limitations of cross-
trial comparisons, both trials essentially replicated the efficacy of
the ‘standard’ bevacizumab regimens observed in E2100 and
RIBBON-1.
At the prespecified interim analysis of the TURANDOT trial,
there was no detectable difference in OS (primary end point)
between treatment groups (Lang et al, 2013). However, BEV–PAC
was significantly superior to BEV–CAP for both PFS and ORR
(secondary end points). We conducted subgroup analyses of
TURANDOT to explore potential differences in the magnitude of
treatment effect according to clinical characteristics. Our aim was
to identify patient populations defined by risk factors that may be
most appropriately treated with one or other regimen. The risk
factors were based largely on an analysis of prognostic factors in
the ATHENA study, in which 42000 patients received first-line
bevacizumab-containing therapy for HER2-negative LR/mBC
(Llombart-Cussac et al, 2013). In ATHENA, the prognostic factors
most closely and robustly associated with worse OS were: liver
metastases or X3 metastatic organs; disease-free interval (DFI)
p24 months; prior anthracycline and/or taxane therapy; and
triple-negative breast cancer (TNBC). The prognostic factor index
enabled identification of patients with a poorer prognosis for
whom particular systemic treatment regimens may be of interest.
MATERIALS AND METHODS
Study design. The design of TURANDOT (ClinicalTrials.gov
NCT00600340) has been published previously (Lang et al, 2013).
Briefly, patients with HER2-negative LR/mBC who had received no
prior chemotherapy for their disease were randomised to either
BEV–PAC (bevacizumab 10mg kg 1, days 1 and 15, plus
paclitaxel 90mgm 2, days 1, 8 and 15, every 4 weeks) or
BEV–CAP (bevacizumab 15mg kg 1 day 1 plus capecitabine
1000mgm 2 twice daily days 1–14, every 3 weeks). Concomitant
endocrine therapy was not permitted. Stratification factors were
oestrogen receptor (ER)/progesterone receptor (PgR) status,
country and menopausal status.
Statistical methods. All analyses were based on the dataset from
the prespecified interim analysis (data cut-off: 1 September 2011).
Efficacy was analysed in the intent-to-treat population (all
randomised patients); safety was analysed in the safety population
(all patients who received at least one dose of study therapy). Post
hoc subgroup analyses were performed according to hormone
receptor status (negative ER, PgR and HER2 (TNBC) vs positive
ER and/or PgR (hormone receptor-positive (HRþ ))).
In additional exploratory analyses, the HRþ population was
further categorised into high-risk and low-risk subgroups, defined,
respectively, as having two or more (high risk) vs one or none (low
risk) of the following four risk factors: DFI p24 months; visceral
metastases; prior (neo)adjuvant anthracycline and/or taxane; or
X3 metastatic organs. These risk factors differ from those
identified in ATHENA. First, as we had already analysed the
subgroup of patients with TNBC (essentially a stratification factor
in TURANDOT (Inbar et al, 2013)) and considered these to be
biologically quite different from the HRþ subgroup, with different
post-study treatment options available, we classified TNBC as one
subgroup and then used the risk factors above as a guide to
subdivide the HRþ subgroup according to the remaining risk
factors. Second, we used visceral metastases rather than liver-only
metastases because lung metastases also showed strong prognostic
value in the ATHENA univariate analysis (P¼ 0.004).
Overall survival and PFS were compared between treatment
arms within the risk groups using Cox proportional hazard
methods and Kaplan–Meier estimates. In multivariate Cox models
for OS, the effect between treatment arms was adjusted for
significant baseline characteristics identified using a stepwise
selection process (level to enter: Po0.1; level to stay: Pp0.05).
Factors were considered for the multivariate selection process only
if Pp0.25 in the univariate Cox analysis. For hazard ratios, 1-year
OS rates and median PFS, 95% confidence intervals (CIs) were
calculated. Cox proportional hazard methods were also used to
analyse the impact of the selected risk groups on OS and PFS in
models including the treatment arms and corresponding interac-
tions. All statistical tests were considered exploratory and no alpha
adjustment for multiple testing was applied.
RESULTS
Patient population and treatment exposure. The intent-to-treat
population included 130 patients (23%) with TNBC and 433 (77%)
with HRþ disease. One patient with PgR-negative disease but
unknown ER status was excluded from the present analysis. Within
the HRþ population, 308 patients (55% of all patients) were
classified as high risk and 125 (22% of all patients) as low risk.
As might be expected in retrospective exploratory subgroup
analyses, there were some imbalances in baseline characteristics
between the treatment arms (Table 1). For example, within the
TNBC cohort, the BEV–PAC arm included fewer patients with
Eastern Cooperative Oncology Group (ECOG) performance status
X1, positive lymph node status, metastatic disease at first
diagnosis or liver metastases compared with the BEV–CAP arm,
but more patients with lung metastases. In the high-risk HRþ
group, the BEV–PAC arm included fewer patients with a DFI
412 months. There were also differences between the cohorts, as
expected when defining cohorts according to risk factors.
Imbalances in the extent of bevacizumab and chemotherapy
exposure were also apparent within and between the treatment
cohorts (Supplementary Appendix Table 1). In the TNBC and
high-risk HRþ cohorts, the median duration of bevacizumab
exposure was longer in the BEV–PAC than the BEV–CAP
treatment arm, whereas chemotherapy exposure was similar in
the two treatment arms. However, in the low-risk HRþ cohort,
the median duration of treatment for both bevacizumab and
chemotherapy was longer in the BEV–CAP treatment arm.
Efficacy. The median duration of follow-up in the TNBC cohort
was 21.4 months in the BEV–PAC arm vs 19.2 months in the
BEV–CAP arm. Corresponding values were 19.0 vs 18.0 months,
respectively, in the high-risk HRþ cohort and 17.3 vs 19.6 months,
respectively, in the low-risk HRþ subgroup.
Analysis of the primary end point OS using a Cox model with
the three-level risk factor and the treatment group showed that the
three risk groups (TNBC, high-risk HRþ and low-risk HRþ ) had
strong prognostic value (P¼ 0.0004) but revealed no significant
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treatment effect (P¼ 0.7847). The OS hazard ratio compared with
TNBC was 0.42 (95% CI 0.27–0.66) for low-risk HRþ and 0.65
(95% CI 0.47–0.89) for high-risk HRþ . No significant interaction
between the three-level risk factor and treatment arms was
observed (P¼ 0.4277) in a corresponding Cox model of OS.
Comparison of OS between the two treatment arms showed
differing treatment effects in the three cohorts, although none of
the treatment effects was statistically significant. In the TNBC
cohort, interim OS results after events in 48% of patients showed a
non-significant trend favouring BEV–PAC (hazard ratio 1.33;
Figure 1 and Table 2). The 1-year OS rate also favoured the
BEV–PAC arm (78% vs 63%). In the multivariate Cox proportional
hazard model adjusted for the significant baseline characteristics
bone metastases (yes vs no) and menopausal status (postmeno-
pausal vs premenopausal), the OS hazard ratio for BEV–CAP vs
BEV–PAC was 1.30 (95% CI 0.77–2.17), supporting the non-
significant trend favouring BEV–PAC observed in the univariate
analysis.
In the HRþ cohort (irrespective of risk status), the OS hazard
ratio for BEV–CAP vs BEV–PAC was 0.95 (95% CI 0.67–1.34)
after events in 30% of patients. In multivariate Cox proportional
hazards analyses of this subgroup, ECOG performance status and
the presence of liver metastases were identified as significant
prognostic factors for OS. The OS hazard ratio was 0.91 (95% CI
0.64–1.31), again supporting the lack of marked OS benefit with
one regimen over another seen in the univariate analysis
(Supplementary Appendix Figure 1). However, when the HRþ
cohort was divided into high- and low-risk subgroups, OS
appeared more favourable with BEV–CAP in the low-risk HRþ
cohort (Figure 1 and Table 2). The OS hazard ratio for BEV–CAP
vs BEV–PAC was 0.80 and 1-year OS rates were 85% with
BEV–PAC vs 90% with BEV–CAP. In contrast, OS outcomes in the
high-risk HRþ cohort were almost identical in the two treatment
arms. These findings were supported by a multivariate Cox analysis
adjusted for significant baseline characteristics (data not shown).
Analysis of PFS, a secondary end point, showed a similar
significant impact for the three risk groups (TNBC, high-risk
HRþ and low-risk HRþ ; Wald chi-squared test, P¼ 0.0002) and
a significant treatment effect favouring BEV–PAC (P¼ 0.0042).
Again, no significant interaction between the risk factors and the
treatment arms was observed (P¼ 0.9665). This finding was
supported in analyses of treatment effect within each risk factor
cohort. Although none of the subgroup differences reached
Table 1. Baseline characteristics according to risk group
TNBC cohort High-risk HRþ Low-risk HRþ
Characteristic
BEV–PAC
(n¼63)
BEV–CAP
(n¼67)
BEV–PAC
(n¼146)
BEV–CAP
(n¼162)
BEV–PAC
(n¼75)
BEV–CAP
(n¼50)
Median age, years (range) 54 (29–84) 56 (28–77) 58 (29–86) 57 (27–79) 61 (33–77) 61 (31–86)
Premenopausal, n (%) 17 (27) 18 (27) 27 (18) 26 (16) 8 (11) 7 (14)
ECOG performance status, n (%)
0 47 (75) 40 (60) 99 (68) 106 (65) 47 (63) 33 (66)
1 13 (21) 24 (36) 39 (27) 51 (31) 23 (31) 16 (32)
2 3 (5) 3 (4) 7 (5) 3 (2) 5 (7) 1 (2)
Disease-free interval, n (%)
p12 months 9 (14) 2 (3) 6 (4) 8 (5) 0 0
412 to p24 months 14 (22) 14 (21) 33 (23) 20 (12) 3 (4) 0
424 months 28 (44) 31 (46) 62 (42) 101 (62) 57 (76) 39 (78)
Nonea 12 (19) 20 (30) 45 (31) 33 (20) 15 (20) 11 (22)
Metastatic at first diagnosis 12 (19) 20 (30) 32 (22) 29 (18) 15 (20) 10 (20)
Metastatic organs, n (%)
X3 26 (41) 28 (42) 76 (52) 93 (57) 2 (3) 3 (6)
Visceral 41 (65) 46 (69) 130 (89) 145 (90) 14 (19) 12 (24)
Liver 17 (27) 29 (43) 89 (61) 91 (56) 7 (9) 6 (12)
Lung 35 (56) 28 (42) 69 (47) 87 (54) 8 (11) 7 (14)
Bone 22 (35) 25 (37) 86 (59) 95 (59) 49 (65) 30 (60)
Lymph nodes 35 (56) 48 (72) 77 (53) 97 (60) 32 (43) 26 (52)
Prior (neo)adjuvant chemotherapy, n (%) 45 (71) 42 (63) 97 (66) 107 (66) 37 (49) 27 (54)
Taxane 19 (30) 14 (21) 32 (22) 32 (20) 6 (8) 4 (8)
Anthracycline 39 (62) 33 (49) 82 (56) 93 (57) 23 (31) 18 (36)
Neither anthracycline nor taxane 4 (6) 6 (9) 9 (6) 11 (7) 13 (17) 9 (18)
Abbreviations: BEV¼bevacizumab; CAP¼ capecitabine; ECOG¼Eastern Cooperative Oncology Group; HRþ ¼ hormone receptor-positive; PAC¼paclitaxel; TNBC¼ triple-negative
breast cancer.
aEither no primary therapy or no response to primary therapy.
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Figure 1. Overall survival (primary end point) according to risk
category and treatment arm. Abbreviations: BEV–CAP¼
bevacizumab–capecitabine; BEV–PAC¼bevacizumab–paclitaxel;
HRþ ¼ hormone-receptor positive; TNBC¼ triple-negative breast
cancer.
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statistical significance, the trend was in the same direction as the
significant PFS benefit observed in the overall population (Figure 2
and Table 2). Objective response rate was also more favourable
with BEV–PAC in the TNBC and high-risk HRþ cohorts, but did
not differ significantly between treatment arms in the low-risk
HRþ cohort (Table 2).
Post-study therapy. In all three cohorts, as in the overall study
population, slightly more patients receiving BEV–CAP than
BEV–PAC received chemotherapy after discontinuing study
therapy (Table 3), consistent with the higher proportion of
patients with disease progression at the time of data cut-off. The
main qualitative difference between treatment arms was the use
of post-progression taxane and capecitabine. Also consistent
with the proportion of patients with disease progression at
the time of data cut-off, the proportion receiving further
chemotherapy was highest in the TNBC cohort, but similar in
the two HRþ cohorts.
Safety. Overall, grade X3 adverse events were less common with
BEV–CAP than with BEV–PAC in all three cohorts (Table 4).
Differences between the treatment arms were driven by the known
safety profiles of the chemotherapy partners, whereas differences
within the treatment arms and between cohorts reflected the
duration of treatment exposure. For example, hand-foot syndrome
was the most common gradeX3 adverse event with BEV–CAP in
all three cohorts, and was most frequent in the low-risk HRþ
cohort. Grade X3 cognitive and neurologic adverse events, of
particular relevance in TNBC, were uncommon in both treatment
arms: the incidence of gradeX3 dizziness was 2% with BEV–PAC
vs 0% with BEV–CAP. Grade X3 epilepsy was reported in 0% vs
1% with BEV–PAC vs BEV–CAP, respectively, and grade X3
speech disorder in 2% vs 0%, respectively.
DISCUSSION
Numerous subgroup analyses of trials evaluating bevacizumab in
LR/mBC have been undertaken in an attempt to identify patients
who benefit most from this treatment option (O’Shaughnessy et al,
2009; Miles et al, 2013).To date, significant OS differences between
bevacizumab vs non-bevacizumab regimens have been elusive,
although it is perhaps unsurprising that exploratory analyses of
small subgroups within trials that were not powered to detect OS
differences even in the overall population yield no significant
differences. The exception was the subgroup of patients previously
exposed to taxanes (Miles et al, 2013), but this finding must be
interpreted with caution given the small sample size, exploratory
nature of these post hoc retrospective analyses and lack of
adjustment for multiple testing.
Rather than adding to the puzzle of determining which patients
should receive bevacizumab, the TURANDOT trial provides an
opportunity to explore which specific bevacizumab-containing
regimen may be most appropriate for a given population.
Bevacizumab-containing therapy is often preferred to chemother-
apy alone in TNBC (Dawood et al, 2012) because of the generally
poor prognosis, lack of effective treatments and high efficacy of
bevacizumab-containing therapies shown in TNBC subgroup
analyses in various treatment settings (Brufsky et al, 2012; von
Minckwitz et al, 2012; Miles et al, 2013). The present analysis
suggests that in these patients at high risk of progression, BEV–
PAC may be a more appropriate option than BEV–CAP, showing a
non-significant trend towards more favourable OS and PFS
compared with BEV–CAP, and a substantially higher ORR (49%
vs 19%). The 1-year OS rate of 78% with BEV–PAC in the TNBC
cohort is among the highest reported in this setting: 1-year OS
rates with non-bevacizumab-containing regimens have not
exceeded 65% in subgroup analyses (O’Shaughnessy et al, 2009,
Table 2. Efficacy outcomes according to risk group
TNBC High-risk HRþ Low-risk HRþ
BEV–PAC
(n¼63)
BEV–CAP
(n¼67)
BEV–PAC
(n¼146)
BEV–CAP
(n¼162)
BEV–PAC
(n¼75)
BEV–CAP
(n¼50)
Overall survival
Events, n (%) 28 (44) 34 (51) 50 (34) 52 (32) 18 (24) 11 (22)
1-Year overall survival rate, % (95% CI) 78 (68–88) 63 (51–75) 80 (74–87) 82 (76–88) 85 (77–93) 90 (81–98)
Hazard ratio (95% CI)a 1.33 (0.80–2.19) 0.97 (0.66–1.43) 0.80 (0.38–1.69)
Progression-free survival
Events, n (%) 50 (79) 54 (81) 93 (64) 125 (77) 33 (44) 35 (70)
Median, months (95% CI) 9.0 (7.8–10.7) 5.6 (4.9–8.0) 11.1 (10.4–13.4) 8.3 (7.1–10.7) 14.4 (10.4–20.5) 11.5 (8.1–16.3)
Hazard ratio (95% CI)a 1.37 (0.93–2.02) 1.29 (0.98–1.69) 1.39 (0.86–2.25)
Objective response
Response rate, % (95% CI) 49 (36–62) 19 (11–31) 46 (38–54) 30 (23–38) 35 (24–47) 28 (16–42)
Difference (95% CI) 30 (14–45) 16 (5–26) 7 ( 10–23)
PD as best response, % 6 25 7 15 5 10
Abbreviations: BEV¼bevacizumab; CAP¼ capecitabine; CI¼ confidence interval; HRþ ¼ hormone receptor-positive; PAC¼paclitaxel; PD¼progressive disease; TNBC¼ triple-negative
breast cancer.
aBEV–CAP vs BEV–PAC, univariate unstratified Cox proportional hazards model.
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Figure 2. Progression-free survival (secondary end point) according to
risk category and treatment arm. Abbreviations: BEV–CAP¼
bevacizumab–capecitabine; BEV–PAC¼bevacizumab–paclitaxel;
HR+¼hormone-receptor positive; TNBC¼ triple-negative breast
cancer.
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Table 4. Summary of grade X3 AEs in 42% of patients in any treatment group in any cohort
TNBC High-risk HRþ Low-risk HRþ
Patients, %
BEV–PAC
(n¼63)
BEV–CAP
(n¼67)
BEV–PAC
(n¼145)
BEV–CAP
(n¼160)
BEV–PAC
(n¼75)
BEV–CAP
(n¼50)
Any grade X3 AE 63.5 41.8 61.4 50.6 61.3 48.0
Hand-foot syndrome 0 11.9 0.7 13.8 0 28.0
Neutropenia 20.6 0 17.9 3.1 16.0 0
Peripheral neuropathy 9.5 0 15.2 0 14.7 2.0
Hypertension 1.6 3.0 4.8 8.1 5.3 2.0
Leucopenia 7.9 0 6.9 0.6 6.7 0
Diarrhoea 1.6 7.5 2.8 3.8 4.0 8.0
Polyneuropathy 4.8 0 3.4 0 5.3 0
Fatigue 1.6 1.5 4.8 1.9 2.7 0
Bone pain 0 1.5 1.4 4.4 2.7 2.0
Syncope 0 0 0 0 1.3 4.0
Pulmonary embolism 1.6 1.5 0.7 1.3 0 4.0
Vomiting 0 1.5 0.7 0.6 4.0 0
GGT increased 0 0 3.4 1.9 0 2.0
Asthenia 1.6 1.5 3.4 1.9 1.3 2.0
Peripheral sensory neuropathy 3.2 0 2.1 0 2.7 0
Nail disorder 3.2 0 2.8 0 2.7 0
Myalgia 3.2 0 0 0 1.3 0
Thrombocytopenia 3.2 3.0 0 1.9 1.3 0
Epistaxis 3.2 0 0 0.6 1.3 0
Pain in extremity 3.2 0 0.7 1.3 1.3 2.0
Anaemia 1.6 3.0 1.4 3.1 0 2.0
Pathological fracture 0 3.0 0 0.6 0 0
Dyspnoea 1.6 3.0 2.8 2.5 0 2.0
Neurotoxicity 1.6 0 0 0 2.7 0
Deep vein thrombosis 0 0 0 2.5 1.3 0
Febrile neutropenia 0 0 2.1 0.6 0 0
Alopecia 1.6 0 2.1 0 0 0
Hypocalcaemia 0 0 2.1 0 0 0
Hypersensitivity 1.6 0 2.1 0 0 0
Abbreviations: AE¼ adverse event; BEV¼bevacizumab; CAP¼ capecitabine; GGT¼gamma-glutamyltransferase; HRþ ¼hormone receptor-positive; PAC¼paclitaxel; TNBC¼ triple-negative
breast cancer.
Table 3. Summary of anti-cancer therapy after discontinuation of study treatment according to risk group
TNBC High-risk HRþ Low-risk HRþ
Patients, n (%)
BEV–PAC
(n¼63)
BEV–CAP
(n¼67)
BEV–PAC
(n¼146)
BEV–CAP
(n¼162)
BEV–PAC
(n¼75)
BEV–CAP
(n¼50)
Bevacizumab 2 (3) 4 (6) 4 (3) 5 (3) 3 (4) 5 (10)
Chemotherapy 32 (51) 40 (60) 57 (39) 79 (49) 30 (40) 25 (50)
Second line 30 (48) 37 (55) 50 (34) 71 (44) 20 (27) 21 (42)
Taxane 3 (5) 16 (24) 2 (1) 45 (28) 2 (3) 12 (24)
Capecitabine 14 (22) 2 (3) 33 (23) 7 (4) 12 (16) 2 (4)
Anthracycline 4 (6) 9 (13) 12 (8) 15 (9) 7 (9) 2 (4)
Platinum 9 (14) 9 (13) 1 (1) 16 (10) 0 1 (2)
Gemcitabine 7 (11) 7 (10) 3 (2) 4 (2) 0 1 (2)
Vinorelbine 3 (5) 7 (10) 3 (2) 10 (6) 0 3 (6)
Other 3 (5) 2 (3) 1 (1) 3 (2) 0 3 (6)
Third line 16 (25) 18 (27) 24 (16) 32 (20) 14 (19) 11 (22)
Abbreviations: BEV¼bevacizumab; CAP¼ capecitabine; HRþ ¼ hormone receptor-positive; PAC¼paclitaxel; TNBC¼ triple-negative breast cancer.
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2011a, b; Baselga et al, 2013). Thus BEV–PAC is a valid, effective
treatment choice, particularly in this setting with limited active
therapies available.
Patients with HER2-negative HRþ disease generally have a
better prognosis. For example, in the E2100 trial median PFS with
paclitaxel alone was 7.7 months in patients with HRþ disease
compared with 5.8 months in the overall population. The addition
of bevacizumab to paclitaxel yielded a median PFS of 11.9 months
and a 54% ORR in the HRþ subgroup of E2100 (Roche data on
file 2007). Furthermore, unlike TNBC, sequential endocrine
therapy is an option in HRþ disease. Nevertheless, this group
represents a highly heterogeneous population and includes patients
with rapidly progressing aggressive disease. Among patients with
high-risk HRþ disease in TURANDOT there was no apparent
difference in OS between the two regimens, but both PFS and ORR
showed non-significant trends favouring BEV–PAC. Patients’
treatment goals may be one of the most important driving factors
in treatment selection, as potential efficacy differences are subtle
and must be balanced against differing safety profiles and patient
preferences. For some patients, the possibility of avoiding taxane
therapy as their first treatment for LR/mBC may represent the key
factor influencing treatment decisions. Although we were unable to
identify any significant difference in quality of life between the
regimens (Lang et al, 2012), clinical experience suggests that
patients may prefer BEV–CAP to BEV–PAC because of the more
acceptable side-effect profile. Moreover, in patients with low-risk
HRþ disease, a trend for better survival was observed with first-
line BEV–CAP.
The failure to detect a difference in quality of life between
regimens in TURANDOTmay be due to a true lack of difference, the
analysis approach adopted for TURANDOT, or insufficient
sensitivity of available quality-of-life instruments to detect subtle
differences in predominantly asymptomatic patients. Nonetheless,
the superior safety profile with BEV–CAP and the trend towards
better OS in a well-defined subset may represent important
considerations when discussing treatment options with such patients.
This conclusion has three major caveats. First, the post hoc
exploratory nature of the analyses means that findings should be
interpreted with caution and regarded as hypothesis-generating.
Nevertheless, the risk factors used to define the low- and
high-risk HRþ subgroups in this analysis are very similar to
those previously identified in ATHENA (Llombart-Cussac et al,
2013). Second, in these interim analyses the numbers of deaths
in each subgroup were relatively small, particularly in the
low-risk group. Third, differences in post-study therapy
between treatment arms and cohorts may dilute the effect on
OS of first-line treatment, particularly in the low-risk HRþ
subgroup in whom long post-progression survival is expected.
It will be interesting to see if these patterns remain evident or
are perhaps strengthened with the final OS analysis anticipated
in 2015.
Notwithstanding these limitations, the simple risk factor index
explored in these analyses of TURANDOT is prognostic for both
PFS and OS. Our findings suggest that such an index may be
used to guide treatment choice when selecting bevacizumab-
containing therapy, balancing outcome with safety and patient
preference.
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